Skip to content

Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace

Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace - a Feasibility Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02898064
Acronym
MAPP
Enrollment
2
Registered
2016-09-13
Start date
2016-12-19
Completion date
2018-05-31
Last updated
2019-07-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

Consenting patients with multiple myeloma (MM) will be randomly allocated to receive either standard medical treatment (chemotherapy, radiotherapy, pain-killing medication) alone or standard medical treatment plus a brace. Patients will be regularly evaluated in research clinics; the results data will inform the design of a full trial. Information will be collected to inform a list of requirements a centre needs to have in place to run an RCT of these interventions.

Detailed description

Multiple myeloma (MM) is a neoplasia of plasma cells mostly within the bone marrow, commonly leading to multiple vertebral collapses. This causes spinal deformity, leading to incapacitating back pain and reduced quality of life. In spite of advances in medical therapy, some patients are left with disabling back pain, sometimes requiring surgical intervention. University Hospitals of North Midlands NHS Trust have observed on an audit of our own practice that application of an external spinal brace as early in the disease process as is possible appears to maintain the overall alignment of the spine, thus minimising risk of spinal deformity and consequent back pain. The ultimate aim is to undertake an RCT to determine whether the use of an external spinal brace can reduce back pain and spine-related disability in patients suffering from back pain due to multiple myeloma, in comparison to conventional management without a brace. However, prior to this, a feasibility study is required. The feasibility study is needed to see if the trial processes (providing patient information, consent process, conducting the baseline investigations and outcome measures) can be accommodated without causing too much delay to the application of the brace. Suitable patients will be consented by the research team and randomised to receive a brace or no brace in addition to their routine Myeloma treatment. After baseline data collection and questionnaires, the participant would be followed up for data collection at 6 weeks and 3 months.

Interventions

DEVICEthoracolumbosacral orthosis or cervicothoracolumbar orthosis

An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used.

OTHERStandard care

Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care

Sponsors

University Hospitals of North Midlands NHS Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adults with MM * Myeloma infiltration in the spine confirmed by radiological evidence * MM-related back pain * Can attend for the whole follow up period

Exclusion criteria

* Presenting with cord compression and neurological deficit requiring urgent decompression and intervention * Chronic pain syndrome * Language barrier that cannot be overcome using translation services * Unwilling or unable to give informed consent * Painful VCFs at the lumbosacral junction, L4 to Sacrum, where application of brace is not possible. Not suitable for treatment with a brace e.g. pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Time from diagnosis to brace fitting for patients randomised to the intervention groupAssessed at 3 months
Number of patients in the intervention arm who request additional support from the orthotic team and time they had to wait for support.assessed at the end of study at 21 months
The number of orthotists in each hospital21 months
Are appropriate braces fitted6 weeksThe locations and levels of VCFs and back pain in patients and the type of brace fitted will be recorded to determine whether appropriate braces are fitted.
Number of appointments issued by orthotists21 months
Frequency of appointments issued by orthotists21 months

Secondary

MeasureTime frameDescription
Qualitative assessment of semi structured interviews in a sub-set of participants, EQ-5D-5L21 months
The number of patients who receive non-study-related interventions during the 3 month follow-up period3 months
The number of new MM cases at each centre1 year
Number of patients eligible for the study during 1 recruitment year.1 year
Disability measured by ODI6 weeks and 3 months
The number of eligible patients who give consent to enter the study21 months
The number of patients that drop-out during follow-up and their reasons21 months
The number of missing cases for a subsequent RCTs co-primary outcomes of pain and disability21 months
Pain measured by VAS6 weeks and 3 months
Descriptive statistics and qualitative analysis of the 3-month follow up patient questionnaire3 monthsThe questionnaire consists principally of ordinal rating scales, which will be analysed descriptively in terms of frequencies, medians and interquartile ranges. Qualitative data from the supplementary open-ended questions will be analysed by means of framework analysis.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026